The biotech whiffs on both revenue and profitability for its first quarter, and indicates more losses are in store.
Image source: The Motley Fool. BioCryst Pharmaceuticals (NASDAQ: BCRX)Q1 2022 Earnings CallMay 05, 2022, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day, and thank you for standing by.
BioCryst (BCRX) delivered earnings and revenue surprises of -2.56% and 1.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?